Generate Biomedicines (NASDAQ:GENB) Shares Gap Up – Still a Buy?

Generate Biomedicines Inc (NASDAQ:GENB)’s stock price gapped up prior to trading on Thursday . The stock had previously closed at $13.02, but opened at $13.62. Generate Biomedicines shares last traded at $13.5090, with a volume of 212,549 shares trading hands.

Wall Street Analyst Weigh In

Several research firms recently commented on GENB. Piper Sandler began coverage on Generate Biomedicines in a report on Tuesday, March 24th. They issued an “overweight” rating and a $24.00 target price on the stock. Wall Street Zen lowered Generate Biomedicines from a “hold” rating to a “sell” rating in a report on Saturday, May 9th. The Goldman Sachs Group began coverage on Generate Biomedicines in a report on Tuesday, March 24th. They issued a “buy” rating and a $26.00 target price on the stock. Cantor Fitzgerald began coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set an “overweight” rating on the stock. Finally, Guggenheim began coverage on Generate Biomedicines in a report on Tuesday, March 24th. They set a “buy” rating and a $30.00 price objective on the stock. Six equities research analysts have rated the stock with a Buy rating and one has assigned a Hold rating to the stock. According to data from MarketBeat, Generate Biomedicines currently has a consensus rating of “Moderate Buy” and a consensus target price of $25.40.

Generate Biomedicines Stock Up 3.9%

The company has a fifty day moving average price of $13.01.

Generate Biomedicines (NASDAQ:GENB) last issued its quarterly earnings data on Thursday, May 7th. The company reported ($1.07) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.48) by ($0.59).

Generate Biomedicines Company Profile

Generate Biomedicines, Inc (NASDAQ: GENB) is a biotechnology company that applies machine learning and generative artificial intelligence to the design and discovery of novel therapeutics. The company develops computational platforms to create and optimize protein sequences and biological molecules with the goal of producing new medicines across a range of modalities. Its core activities center on algorithm-driven design, iterative experimental validation, and the translation of computational outputs into candidate therapeutic molecules.

Generate’s technology combines advanced computational models with high-throughput laboratory methods to accelerate discovery and improve the likelihood of producing viable drug candidates.